U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H32N6O4S
Molecular Weight 560.6694
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUIZARTINIB

SMILES

CC(C)(C)c1cc(=NC(=O)Nc2ccc(cc2)-c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6)[nH]o1

InChI

InChIKey=CVWXJKQAOSCOAB-UHFFFAOYSA-N
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19654408 | https://www.ncbi.nlm.nih.gov/pubmed/23497317

Quizartinib (AC220) is an orally bioavailable, small molecule receptor tyrosine kinase inhibitor that is being developed by Daiichi Sankyo Company (previously Ambit Biosciences) and Astellas Pharma as a treatment for acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) and advanced solid tumours. The highest affinity target identified for Quizartinib was FLT3. The only other kinases with binding constants within 10-fold that for FLT3 were the closely related receptor tyrosine kinases KIT, PDGFRA, PDGFRB, RET, and CSF1R. Kinase inhibition of (mutant) KIT, PDGFR and FLT3 isoforms by quizartinib leads to potent inhibition of cellular proliferation and induction of apoptosis in in vitro leukemia models as well as in native leukemia blasts treated ex vivo.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
400 ng × eq/g
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUIZARTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10000 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUIZARTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.5 day
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUIZARTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Hyperglycemia, Fatigue...
Other AEs:
Hyperglycemia (25%)
Fatigue (62.5%)
Dysgeusia (25%)
Nausea (37.5%)
Vomiting (25%)
Edema peripheral (25%)
Peripheral sensory neuropathy (12.5%)
Anemia (25%)
Neutropenia (25%)
Electrocardiogram QT prolonged (12.5%)
Tumor pain (12.5%)
Abdominal distension (12.5%)
Leukopenia (12.5%)
Thrombocytopenia (12.5%)
Dyspnea (12.5%)
Pain in extremity (12.5%)
Sources:
250 mg 1 times / day multiple, oral (mean)
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 25
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 25
Sources:
Other AEs: Fatigue, Photosensitivity...
Other AEs:
Fatigue (grade 3, 4%)
Photosensitivity (grade 3, 4%)
Thrombocytopenia (grade 3, 4%)
Sources:
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 8
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 8
Sources:
DLT: Electrocardiogram QTc interval prolonged...
Dose limiting toxicities:
Electrocardiogram QTc interval prolonged (grade 3, 38%)
Sources:
200 mg 1 times / day multiple, oral
MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Median age 52.4 years
n = 17
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52.4 years
Sex: M+F
Population Size: 17
Sources:
DLT: Electrocardiogram QTc interval prolonged...
Dose limiting toxicities:
Electrocardiogram QTc interval prolonged (grade 3, 24%)
Sources:
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Disc. AE: Pneumonia, Intracranial haemorrhage...
Other AEs: Nausea, Fatigue...
AEs leading to
discontinuation/dose reduction:
Pneumonia (2%)
Intracranial haemorrhage (2%)
Graft versus host disease (2%)
Septic shock (2%)
QT interval prolonged (grade 2, 1%)
QT interval prolonged (5%)
QT interval prolonged (9%)
Other AEs:
Nausea (grade 3, 2%)
Fatigue (grade 3, 8%)
Thrombocytopenia (grade 3, 5%)
Thrombocytopenia (grade 4, 30%)
Thrombocytopenia (grade 5, <1%)
Pyrexia (grade 3, 2%)
Musculoskeletal pain (grade 3, 4%)
Anaemia (grade 3, 29%)
Anaemia (grade 4, 1%)
Febrile neutropenia (grade 3, 28%)
Febrile neutropenia (grade 4, 2%)
Neutropenia (grade 3, 5%)
Neutropenia (grade 4, 27%)
Vomiting (grade 3, 3%)
Hypokalaemia (grade 3, 11%)
Hypokalaemia (grade 4, 1%)
Diarrhoea (grade 3, 2%)
Electrocardiogram QT prolonged (grade 3, 4%)
Cough (grade 3, <1%)
Rash (grade 3, 2%)
Abdominal pain (grade 3, 2%)
Headache (grade 3, <1%)
Septic shock (grade 3, 11%)
Septic shock (grade 4, 6%)
Septic shock (grade 5, 2%)
Oedema peripheral (grade 3, 3%)
Decreased appetite (grade 3, 2%)
Dyspnoea (grade 3, 5%)
Dyspnoea (grade 4, <1%)
White blood cell count decreased (grade 3, 5%)
White blood cell count decreased (grade 4, 12%)
Stomatitis (grade 3, 2%)
Stomatitis (grade 4, <1%)
Pneumonia (grade 3, 7%)
Pneumonia (grade 4, 1%)
Pneumonia (grade 5, 4%)
ALT increased (grade 3, 4%)
Hypotension (grade 3, 3%)
Hypotension (grade 4, <1%)
Graft versus host disease (grade 3, 3%)
Graft versus host disease (grade 4, 1%)
Graft versus host disease (grade 5, 1%)
Hypocalcaemia (grade 3, <1%)
Petechiae (grade 3, 1%)
Weight decreased (grade 3, 1%)
Hypophosphataemia (grade 3, 4%)
Hypophosphataemia (grade 4, <1%)
Hyponatremia (grade 3, 3%)
Hyponatremia (grade 4, <1%)
Urinary tract infection (grade 3, 4%)
Urinary tract infection (grade 4, <1%)
Upper respiratory tract infection (grade 3, 2%)
Cellulitis (grade 3, 3%)
Hyperglycaemia (grade 3, 1%)
Hyperglycaemia (grade 4, 1%)
Leukocytosis (grade 3, 2%)
Leukocytosis (grade 4, 1%)
Leukocytosis (grade 5, <1%)
Acute renal failure (grade 3, 1%)
Acute renal failure (grade 4, <1%)
Acute renal failure (grade 5)
Pancytopenia (grade 3, 5%)
Syncope (grade 3, 4%)
Clostridioides difficile infection (grade 3, 2%)
Clostridioides difficile infection (grade 4, <1%)
Device related infection (grade 3, 3%)
Lymphocyte count decreased (grade 3, 2%)
Lymphocyte count decreased (grade 4, 1%)
Intracranial haemorrhage (grade 4, 1%)
Intracranial haemorrhage (grade 5, 2%)
Pneumonia fungal (grade 3, 2%)
Respiratory distress (grade 3, 1%)
Respiratory distress (grade 4, <1%)
Respiratory distress (grade 5, 1%)
Sources:
135 mg 1 times / day multiple, oral
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, Median age 56 years
n = 5
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 56 years
Sex: M+F
Population Size: 5
Sources:
DLT: Pancytopenia, Electrocardiogram QT prolonged...
Dose limiting toxicities:
Pancytopenia (grade 3, 20%)
Electrocardiogram QT prolonged (grade 3, 20%)
Febrile neutropenia (20%)
Sources:
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources:
unhealthy, Median age 57.8 years
n = 6
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 57.8 years
Sex: M+F
Population Size: 6
Sources:
Other AEs: Electrocardiogram QTc interval prolonged...
Other AEs:
Electrocardiogram QTc interval prolonged (33.3%)
Sources:
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Other AEs: Vomiting, Anorexia...
Other AEs:
Vomiting (grade 3, 3%)
Anorexia (grade 3, 3%)
Fatigue (grade 3, 3%)
Anemia (grade 3, 6%)
Hypocalcemia (grade 3, 3%)
Pyrexia (grade 3, 3%)
Pancytopenia (grade 3, 3%)
Sources:
316.7 mg 1 times / day multiple, oral (mean)
Dose: 316.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 316.7 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: acute myeloid leukemia
Sex: M+F
Population Size: 16
Sources:
Other AEs: Anemia, Eyelid edema...
Other AEs:
Anemia (grade 3, 6%)
Eyelid edema (grade 3, 6%)
Hypoalbuminemia (grade 3, 6%)
Lung infection (grade 3, 6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Dyspnea 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Electrocardiogram QT prolonged 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Leukopenia 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Pain in extremity 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Peripheral sensory neuropathy 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Tumor pain 12.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Anemia 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Dysgeusia 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Edema peripheral 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Hyperglycemia 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Neutropenia 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Vomiting 25%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Nausea 37.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Fatigue 62.5%
90 mg 1 times / day multiple, oral
MTD
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, Median age 49.5 years
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 49.5 years
Sex: M+F
Population Size: 8
Sources:
Fatigue grade 3, 4%
250 mg 1 times / day multiple, oral (mean)
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 25
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 25
Sources:
Photosensitivity grade 3, 4%
250 mg 1 times / day multiple, oral (mean)
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 25
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 3, 4%
250 mg 1 times / day multiple, oral (mean)
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 25
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 25
Sources:
Electrocardiogram QTc interval prolonged grade 3, 38%
DLT
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, Median age 52 years
n = 8
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52 years
Sex: M+F
Population Size: 8
Sources:
Electrocardiogram QTc interval prolonged grade 3, 24%
DLT
200 mg 1 times / day multiple, oral
MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Median age 52.4 years
n = 17
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 52.4 years
Sex: M+F
Population Size: 17
Sources:
Graft versus host disease 2%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Intracranial haemorrhage 2%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pneumonia 2%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Septic shock 2%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
QT interval prolonged 5%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
QT interval prolonged 9%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
QT interval prolonged grade 2, 1%
Disc. AE
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Acute renal failure grade 3, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hyperglycaemia grade 3, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Petechiae grade 3, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Respiratory distress grade 3, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Weight decreased grade 3, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypokalaemia grade 3, 11%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Septic shock grade 3, 11%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Abdominal pain grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Clostridioides difficile infection grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Decreased appetite grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Diarrhoea grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Leukocytosis grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Lymphocyte count decreased grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Nausea grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pneumonia fungal grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pyrexia grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Rash grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Stomatitis grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Upper respiratory tract infection grade 3, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Febrile neutropenia grade 3, 28%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Anaemia grade 3, 29%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Cellulitis grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Device related infection grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Graft versus host disease grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hyponatremia grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypotension grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Oedema peripheral grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Vomiting grade 3, 3%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
ALT increased grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Electrocardiogram QT prolonged grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypophosphataemia grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Musculoskeletal pain grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Syncope grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Urinary tract infection grade 3, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Dyspnoea grade 3, 5%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Neutropenia grade 3, 5%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pancytopenia grade 3, 5%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Thrombocytopenia grade 3, 5%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
White blood cell count decreased grade 3, 5%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pneumonia grade 3, 7%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Fatigue grade 3, 8%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Cough grade 3, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Headache grade 3, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypocalcaemia grade 3, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Anaemia grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Graft versus host disease grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hyperglycaemia grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypokalaemia grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Intracranial haemorrhage grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Leukocytosis grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Lymphocyte count decreased grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pneumonia grade 4, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
White blood cell count decreased grade 4, 12%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Febrile neutropenia grade 4, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Neutropenia grade 4, 27%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Thrombocytopenia grade 4, 30%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Septic shock grade 4, 6%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Acute renal failure grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Clostridioides difficile infection grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Dyspnoea grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hyponatremia grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypophosphataemia grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Hypotension grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Respiratory distress grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Stomatitis grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Urinary tract infection grade 4, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Acute renal failure grade 5
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Graft versus host disease grade 5, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Respiratory distress grade 5, 1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Intracranial haemorrhage grade 5, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Septic shock grade 5, 2%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Pneumonia grade 5, 4%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Leukocytosis grade 5, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Thrombocytopenia grade 5, <1%
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Median age 55 years
n = 241
Health Status: unhealthy
Condition: acute myeloid leukaemia
Age Group: Median age 55 years
Sex: M+F
Population Size: 241
Sources:
Febrile neutropenia 20%
DLT
135 mg 1 times / day multiple, oral
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, Median age 56 years
n = 5
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 56 years
Sex: M+F
Population Size: 5
Sources:
Electrocardiogram QT prolonged grade 3, 20%
DLT, Disc. AE
135 mg 1 times / day multiple, oral
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, Median age 56 years
n = 5
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 56 years
Sex: M+F
Population Size: 5
Sources:
Pancytopenia grade 3, 20%
DLT, Disc. AE
135 mg 1 times / day multiple, oral
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, Median age 56 years
n = 5
Health Status: unhealthy
Condition: solid tumors
Age Group: Median age 56 years
Sex: M+F
Population Size: 5
Sources:
Electrocardiogram QTc interval prolonged 33.3%
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources:
unhealthy, Median age 57.8 years
n = 6
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 57.8 years
Sex: M+F
Population Size: 6
Sources:
Anorexia grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Fatigue grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Hypocalcemia grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Pancytopenia grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Pyrexia grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Vomiting grade 3, 3%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Anemia grade 3, 6%
73.5 mg 1 times / day multiple, oral (mean)
Dose: 73.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 73.5 mg, 1 times / day
Sources:
unhealthy, Median age 64 years
n = 35
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: Median age 64 years
Sex: M+F
Population Size: 35
Sources:
Anemia grade 3, 6%
316.7 mg 1 times / day multiple, oral (mean)
Dose: 316.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 316.7 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: acute myeloid leukemia
Sex: M+F
Population Size: 16
Sources:
Eyelid edema grade 3, 6%
316.7 mg 1 times / day multiple, oral (mean)
Dose: 316.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 316.7 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: acute myeloid leukemia
Sex: M+F
Population Size: 16
Sources:
Hypoalbuminemia grade 3, 6%
316.7 mg 1 times / day multiple, oral (mean)
Dose: 316.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 316.7 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: acute myeloid leukemia
Sex: M+F
Population Size: 16
Sources:
Lung infection grade 3, 6%
316.7 mg 1 times / day multiple, oral (mean)
Dose: 316.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 316.7 mg, 1 times / day
Sources:
unhealthy
n = 16
Health Status: unhealthy
Condition: acute myeloid leukemia
Sex: M+F
Population Size: 16
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes (co-administration study)
Comment: The PBPK results indicated that coadministration of rifampin, a strong CYP3A inducer, with quizartinib would result in an approximately 72% decrease in quizartinib exposure and an approximately 66% decrease in AC886 exposure (AUCinf)
Page: -
yes
yes (co-administration study)
Comment: Steady‐state PK simulation demonstrated ~2‐fold increase of both steady–state Cmax and AUC from time 0 to the end of the dosing interval when quizartinib was administered with ketoconazole due to accumulation of quizartinib at steady state. When administered with fluconazole, geometric mean ratios (90% confidence interval) for quizartinib Cmax and AUC from time 0 extrapolated to infinity were 111% (100%, 124%) and 120% (104%, 138%), respectively, vs quizartinib alone.
Page: -
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
2009 Dec 10
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
2009 Oct 1
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
2011 Oct 27
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
2014 Oct
Patents

Sample Use Guides

60 mg daily was selected as the highest dose for continuous daily administration based on Phase 2 study data in relapsed or refractory acute myeloid leukaemia patients. Quizartinib was well tolerated at daily doses ≤ 200 mg/day in patients with relapsed or refractory acute myeloid leukaemia patients (Phase I study).
Route of Administration: Oral
Both of the FLT3-ITD cell lines, MV4-11 and MOLM-14, were exquisitely sensitive to quizartinib treatment with cell viability IC50 values of 0.1 to 0.3 nmol/L measured at 72 hours. Interestingly, while an IC50 of 0.4 nmol/L could be measured after 72 hours in SEM-K2 cells, complete loss of viability required 5 to 7 days. In contrast, minimal or no loss of viability was observed in the FLT3-WT–expressing RS4;11 and THP-1 cells, even following 7 days of quizartinib treatment, consistent with reports that these lines are not dependent on FLT3 signaling for sustained cell growth
Name Type Language
QUIZARTINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
AC010220
Code English
AC-010220
Code English
1-(5-TERT-BUTYL-1,2-OXAZOL-3-YL)-3-(4-(7-(2-(MORPHOLIN-4-YL)ETHOXY)IMIDAZO(2,1-B)(1,3)BENZOTHIAZOL-2-YL)PHENYL)UREA
Systematic Name English
AC220
Code English
UREA, N-(5-(1,1-DIMETHYLETHYL)-3-ISOXAZOLYL)-N'-(4-(7-(2-(4-MORPHOLINYL)ETHOXY) IMIDAZO(2,1-B)BENZOTHIAZOL-2-YL)PHENYL)-
Common Name English
AC-220
Code English
ASP-2689
Code English
N-(5-(1,1-DIMETHYLETHYL)ISOXAZOL-3-YL)-N'-(4-(7-(2-(MORPHOLIN-4-YL)ETHOXY)IMIDAZO(2,1- B)BENZOTHIAZOL-2-YL)PHENYL)UREA
Systematic Name English
QUIZARTINIB [WHO-DD]
Common Name English
QUIZARTINIB [USAN]
Common Name English
QUIZARTINIB [INN]
Common Name English
N-(5-TERT-BUTYLISOXAZOL-3-YL)-N'-(4-(7-(2-(MORPHOLIN-4-YL)ETHOXY)IMIDAZO(2,1-B)(1,3)BENZOTHIAZOL-2-YL)PHENYL)UREA
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
Code System Code Type Description
FDA UNII
7LA4O6Q0D3
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
WIKIPEDIA
QUIZARTINIB
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
CAS
950769-58-1
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
DRUG CENTRAL
5341
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
EVMPD
SUB89721
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
NCI_THESAURUS
C68936
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
DRUG BANK
DB12874
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL576982
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
PUBCHEM
24889392
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
MESH
C544967
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
EPA CompTox
950769-58-1
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY
INN
9356
Created by admin on Sat Jun 26 14:40:39 UTC 2021 , Edited by admin on Sat Jun 26 14:40:39 UTC 2021
PRIMARY